% alzhub.org library filter
% Source: https://alzhub.org/research?author=Sperling+R&about=side-effects
% 6 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{sperling2021-33464300,
  author  = {Sperling, R. and Henley, D. and Aisen, P. S. and Raman, R. and Donohue, M. C. and Ernstrom, K. and Rafii, M. S. and Streffer, J. and others},
  title   = {{Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2021},
  doi     = {10.1001/jamaneurol.2020.4857},
  pmid    = {33464300},
  url     = {https://doi.org/10.1001/jamaneurol.2020.4857}
}

@article{salloway2018-29914022,
  author  = {Salloway, S. P. and Sperling, R. and Fox, N. C. and Sabbagh, M. N. and Honig, L. S. and Porsteinsson, A. P. and Rofael, H. and Ketter, N. and others},
  title   = {{Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2018},
  doi     = {10.3233/jad-171157},
  pmid    = {29914022},
  url     = {https://doi.org/10.3233/jad-171157}
}

@article{liu2018-29429971,
  author  = {Liu, E. and Wang, D. and Sperling, R. and Salloway, S. and Fox, N. C. and Blennow, K. and Scheltens, P. and Schmidt, M. E. and others},
  title   = {{Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab}},
  journal = {Neurology},
  year    = {2018},
  doi     = {10.1212/wnl.0000000000005060},
  pmid    = {29429971},
  url     = {https://doi.org/10.1212/wnl.0000000000005060}
}

@article{vandyck2025-41355080,
  author  = {van Dyck, C. H. and Sperling, R. and Johnson, K. and Dhadda, S. and Kanekiyo, M. and Li, D. and Gee, M. and Hersch, S. and Irizarry, M. and Kramer, L.},
  title   = {{Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension study}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70905},
  pmid    = {41355080},
  url     = {https://doi.org/10.1002/alz.70905}
}

@article{sperling2012-22305802,
  author  = {Sperling, R. and Salloway, S. and Brooks, D. J. and Tampieri, D. and Barakos, J. and Fox, N. C. and Raskind, M. and Sabbagh, M. and others},
  title   = {{Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis}},
  journal = {The Lancet. Neurology},
  year    = {2012},
  doi     = {10.1016/s1474-4422(12)70015-7},
  pmid    = {22305802},
  url     = {https://doi.org/10.1016/s1474-4422(12)70015-7}
}

@article{brashear2018-30412493,
  author  = {Brashear, H. R. and Ketter, N. and Bogert, J. and Di, J. and Salloway, S. P. and Sperling, R.},
  title   = {{Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2018},
  doi     = {10.3233/jad-180675},
  pmid    = {30412493},
  url     = {https://doi.org/10.3233/jad-180675}
}